On this very special extended Coliseum Quick Cast we officially announce the latest addition to the Investors Coliseum family Mindset Pharma Inc. We also will be sitting down and talking to James Lanthier Chief Executive Officer for Mindset Pharma Inc. James will be talking to us about who Mindset is and where exactly they are positioned in this very hectic and fast paced growing Psychedelic Industry. Subscribers and Investors wont want to miss this company!
ABOUT MINDSET PHARMA INC. (CSE:MSET) (FSE:9DF) (OTCQB:MSSTF)
Mindset Pharma is a Toronto-based drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Founded in 2019 by domain experts in drug development, medicinal chemistry and capital markets, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely. Classic psychedelics will likely be approved for medical use in the near future, however, they are not optimized as pharmaceuticals and cannot be patented as they are in the public domain .Mindset is applying innovative medicinal chemistry to create a pipeline of optimized psychedelic medications with improved efficacy and reduced toxicity. Mindset has developed a patent-pending chemical synthesis process to address a pressing need for scalable, pharmaceutical grade, low-cost psilocybin
